CLAZF.US Claritas Pharmaceuticals Inc
- Market cap
- USD 3.66K
- P/E
- -
- P/B
- 0.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is CLAZF.US undervalued?
Graham numberThe Graham number of Claritas Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Claritas Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Claritas Pharmaceuticals Inc yet.
Claritas Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Claritas Pharmaceuticals Inc
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Full company profileClaritas Pharmaceuticals Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Claritas Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 475K | - | - | - | - | 0.00 | 0.00 | 0.00 | - | - | - |
| Gross Profit | 475K | - | -807.73 | -18.9K | - | - | - | - | - | - | - |
| Operating Income | -13.6M | -131K | -1.40M | -12.0M | -14.5M | -11.1M | -9.45M | -3.28M | - | - | - |
| EBITDA | -6.28M | -48.9K | -1.40M | -11.4M | -15.4M | 17.7M | -16.7M | 18.2M | - | - | - |
| Net Income | -20.0M | -51.3K | -1.40M | -11.6M | -31.9M | 6.94M | -21.2M | 4.21M | - | - | - |
| EPS | -184 | -0.47 | -1.92 | -7.86 | -5.13 | 0.64 | -0.95 | 0.16 | - | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 3.42M | 50.8K | 641K | 4.81M | 65.3M | 59.6M | 25.3M | 10.4M | - | - | - |
| Total Liabilities | 4.63M | 1.29M | 200K | 1.90M | 76.9M | 49.8M | 28.7M | 8.94M | - | - | - |
| Shareholders' Equity | -1.22M | -1.24M | 441K | 2.92M | -11.6M | 9.76M | -3.44M | 1.51M | - | - | - |
| Cash & Short-term Investments | 232K | 28.3K | 622K | 673K | 3.69M | 227K | 32.0K | 5.00K | - | - | - |
| Total Debt | - | - | - | - | 2.87M | 246K | 736K | 925K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.71M | -1.48M | -1.13M | -1.64M | -5.56M | -4.85M | -6.48M | -309K | - | - | - |
| Capital Expenditure | 4.03M | 0.00 | 20.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Free Cash Flow | -9.74M | -1.48M | -1.13M | -1.64M | -5.56M | -4.85M | -6.48M | -309K | - | - | - |
| Ratios | |||||||||||
| ROE | - | - | -318.4% | -396.1% | - | 71.0% | - | 279.4% | - | - | - |
| ROA | -585.7% | -101.0% | -219.0% | -240.0% | -48.8% | 11.6% | -84.0% | 40.3% | - | - | - |
| Net Profit Margin | -4,211.6% | - | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | 0.03x | - | 0.61x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Claritas Pharmaceuticals Inc dividends
Claritas Pharmaceuticals Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:20 on Jul 23, 2021.
Who owns Claritas Pharmaceuticals Inc
- Insiders 0.26%
- Institutions 0.00%
- Public & others 99.74%
- Shares outstanding 36.6M
- Free float 30.4M
Claritas Pharmaceuticals Inc company profile
- Company name
- Claritas Pharmaceuticals Inc
- Ticker
- CLAZF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 4040 Civic Center Drive, San Rafael, CA, United States, 94903
- Phone
- 888 861 2008
- Website
- claritaspharma.com
About Claritas Pharmaceuticals Inc
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Claritas Pharmaceuticals Inc management
7- Mr. Robert Farrell J.D.Chairman, CEO & President
- Ms. Victoria Diana RudmanInterim CFO, Treasurer & Secretary · born 1968
- Mr. Seth YakatanCo-Founder · born 1970
- Dr. Stuart L. Silverman FACP, FACR, M.D.Chair of Scientific Advisory Board and Vice President of Medical Affairs · born 1947
- Dr. Sari Prutchi-Sagiv Ph.D.Chief Scientific Officer
- Dr. Moshe Yeshurun M.D.Chief Medical Officer
- Dr. Amos Rosenthal Ph.D.Head of Chemistry